Skip to main content
Premium Trial:

Request an Annual Quote

Taiwanese Dx Firm Micronbrane Medical Closes $4.5M Series A Financing Round

Due to an error in the press release, CDIB Capital Healthcare Ventures' name was incorrectly reported and has been corrected.

NEW YORK – Taiwan-based diagnostic firm Micronbrane Medical announced on Wednesday that it raised $4.5 million in a Series A funding round.

The round was led by investment management firm CDIB Capital Healthcare Ventures. 

The firm said in a statement that it is working on clinical testing of its PaRTI-Seq (Pathogen Real-Time Identification by Sequencing) products with two medical centers in Taiwan. PaRTI-Seq includes consumables and reagents for end-user clinical diagnostic testing. The PaRTI-Seq assay uses next-generation sequencing to identify pathogens within 24 hours, for clinical use.

Within the next two years, the company plans to hold US clinical studies for the PaRTI-Seq test and to enter the US and Europe commercial markets with its research-use-only products. The company currently offers its Devin fractionation filter for depletion of host DNA interference from whole-blood samples and a kit for microbial DNA extraction and enrichment. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.